C-reactive protein, cardiovascular disease and stroke: New roles for an old biomarker

Expert Review of Neurotherapeutics

Volumn 4, Issue 3, 2004, Pages 507-518

  Willcox, Bradley J ^a,b,c   Abbott, Robert D ^a,d   Yano, Katsuhiko ^a,b   Rodriguez, Beatriz L ^a,b,c   Willcox, D Craig ^e   Curb, J David ^a,b,c  

^a PACIFIC HEALTH RESEARCH INSTITUTE   (United States)

^b KUAKINI MEDICAL CENTER   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e Okayama Prefectural University   (Japan)

Author keywords

Aspirin; C reactive protein; Cardiovascular disease; Elderly; hsCRP; Inflammation; Mortality; Risk factor; Statin; Stroke

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; ALTEPLASE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; CHOLESTEROL; CLOPIDOGREL; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; FIBRINOLYTIC AGENT; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ECHOCARDIOGRAPHY; HUMAN; INCIDENCE; INFLAMMATION; MAGNETIC RESONANCE ANGIOGRAPHY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; STROKE; SUBARACHNOID HEMORRHAGE; SURVIVAL;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; HUMANS; RISK FACTORS;

EID: 2342604932     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.3.507     Document Type: Review

References (92)

1. World Health Organization. Stroke 1989. Recommendations on stroke prevention, diagnosis and therapy. Report of the WHO Task Force on stroke and other cerebrovascular disorders. Stroke 20, 1407-1431 (1989).
2. Sard C, Rastenyte D, Cepaitis Z et al. International trends in mortality from stroke, 1968 to 1994. Stroke 31, 1588-1601 (2000).
3. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat. Q. 41, 155-168 (1988).
4. Howard G, Howard VJ, Katholi C et al. Decline in US stroke mortality: an analysis of temporal patterns by sex, race and geographic regions. Stroke 32, 2213-2210 (2001).
5. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur. Heart J. 18, 1231-1248 (1997).
6. Klag MJ, Whelton PK, Seidler AJ. Decline in US stroke mortality: demographic trends and antihypertensive treatment. Stroke 20, 14-21 (1989).
7. American Heart Association. Stroke. In: Heart Disease and Stroke Statistics - 2003 Update. American Heart Association, TX, USA (2003).
8. Rodriguez BL, D'Agostino R, Abbott RD, et al. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: a comparison of incidence and risk factor effects. Stroke 33, 236-237 (2002). Interesting paper that shows Japanese-American men now have a lower stroke risk than Caucasians.
9. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA 288, 1388-1395 (2002). Excellent review of risk factors for stroke and relative efficacy of treatment.
10. World Population Ageing. 1950-2050. United Nations, 2002. Department of Economic and Social Affairs Population Division. United Nations Publication Sales No. E.02.XIII.3.
11. Fassbender K, Bertsch T, Mielke O et al. Adhesion molecules in cerebrovascular diseases: evidence for an inflammatory endothelial activation in cerebral large- and small-vessel disease. Stroke 30, 1647-1650 (1999).
12. Stary HC, Chandler AB, Glagov S et al. A definition of initial, fatty streak and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 89, 2462-2478 (1994).
13. Napoli C, D'Armiento FP, Mancini FP et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J. Clin. Invest. 100, 2680-2690 (1997).
14. Newman AB, Arnold AM, Naydeck BL et al. Cardiovascular Health Study Research Group. 'Successful aging': effect of subclinical cardiovascular disease. Arch. Intern. Med. 163, 2315-2322 (2003). Interesting paper that links C-reactive protein (CRP) to subclinical cardiovascular disease (CVD) and looks at its impact on disability in older age.
15. Bernstein AM, Willcox BJ, Tamaki H et al. Autopsy of an Okinawan-Japanese centenarian: absence of many age-related diseases. J. Gerontol. Med. Sci. (2004) (In Press). Interesting paper that shows the remarkable age range at which CVD can develop in humans and the potential resistance to CVD in centenarians.
16. Blake GJ, Ridker PM. Inflammatory biomarkers and cardiovascular risk prediction. J. Intern. Med. 252, 283-294 (2002).
17. Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke 34, 2518-2532 (2003). Excellent current review of this topic including the role of CRP in CVD.
18. Rohde LE, Hennekens CH, Ridker PM. Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. Arterioscler. Thromb. Vasc. Biol. 19, 1595-1599 (1999).
19. Hackman A, Abe Y, Insull W Jr et al. Levels of soluble adhesion molecules in patients with dyslipidemia. Circulation 93, 1334-1338 (1996).
20. Ferri C, Desideri G, Valenti M et al. Early upregulation of endothelial adhesion molecules in obese hypertensive men. Hypertension 34, 568-573 (1999).
21. Grayson JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J. Infect. Dis. 181, S402-S410 (2000).
22. Yamashita K, Ouchi K, Shirai M et al. Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery. Stroke 29, 773-778 (1998).
23. Virok D, Ki values Z, Karai L et al. Chlamydia pneumoniae in atherosclerotic middle cerebral artery. Stroke 32, 1973-1976 (2001).
24. Muhlestein JB, Anderson JL. Infectious serology and atherosclerosis: how burdensome is the risk? Circulation 107, 220-222 (2003).
25. Tohgi H, Konno S, Takahashi S et al. Activated coagulation/fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels. Thrombosis Res. 100, 373-379 (2000).
26. Walsh PN, Schmaier AH. Platelet-coagulant protein interactions. In: Haemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VS. (Eds). JB Lippincott, PA, USA 689-709 (1987).
27. Booth NA, Simpson AJ, Croll A et al. Plasminogen activator inhibitor in plasma and platelets. Br. J. Haematol. 70, 327-333 (1988).
28. Lagrand WK, Visser CA, Hermens WT et al. C-reactive protein as a cardiovascular risk factor. More than an epiphenomenon? Circulation 100, 96-102 (1999).
29. Warlow C, Sudlow C, Dennis M et al. Stroke. Lancet 362, 1211-1224 (2003).
30. Harbison J, Hossain O, Jenkinson D et al. Diagnostic accuracy of stroke referrals from primary care, emergency room physicians and ambulance staff using the face arm speech test. Stroke 34, 71-76 (2003).
31. Von Kummer R, Bourguain H, Bastianello S et al., for the European Co-operative Acute Stroke Study II Group. Early prediction of irreversible brain damage after ischemic stroke at CT. Radiology 219, 95-100 (2001).
32. Lyden P. Early major ischemic changes on computed tomography should not preclude use of tissue plasminogen activator. Stroke 34, 821-822 (2003).
33. Tomsick TA. Tick tock, doc: the rapid evaluation of acute stroke to direct therapy and improve patient outcome. AJNR 21, 1177-1179 (2000).
34. Atlas SW, Thulborn KR. MR detection of hyperacute parenchymal hemorrhage of the brain. AJNR 19, 1471-1477 (1998).
35. Soong JC, Bradley WG, Chen DY et al. FLAIR should be more sensitive than CT for the detection of acute subaradmoid hemorrhage. Radiology 209, 471 (1998).
36. Marler JR, Tilley BC, Lu M et al. Early stroke treatment associated with better outcome: the NINDS rtPA stroke study. Neurology 55, 1649-1655 (2000).
37. National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333, 1581-1587 (1995).
38. Connors JJ III. Interventional stroke therapy: the potential benefit of direct intra-arterial infusion. Rev. Cardiovasc. Med. 3(Suppl. 2), S92-S99 (2002).
39. Chen ZM, Sandercook P, Pan HC et al. Indication for early aspirin use in acute ischemic stroke: a combined analysis of 40000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 31, 1240-1249 (2000).
40. Kerber CW, Barr JD, Berger RM, Chopko BW. Snare retrieval of intracranial thrombus in patients with acute stroke. J. Vasc. Interv. Radiol. 13, 1269-1274 (2002). A new and exciting area of potential therapy for acute stroke.
41. Gorelick PB, Sacco RL, Smith DB et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 281, 1112-1120 (1999).
42. Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355, 865-872 (2000).
43. Schatz IJ, Masaki K, Yano K et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 358, 351-355 (2001).
44. Benfante R, Yano K, Hwang LJ et al. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men: implications of shared risk. Stroke 25, 814-820 (1994).
45. Hankey JG, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs and effects on individuals and populations. Lancet 354, 1457-1463 (1999).
46. Gueyffier F, Bulpitt C, Boissel JP et al., for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomized controlled trials. Lancet 353, 793-796 (1999).
47. Arenillas JF, Alvarez-Sabin J, Molina CA et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke 34, 2463-2470 (2003).
48. Rost NS, Wolf PA, Kase CS et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: The Framingham Study. Stroke 32, 2575-2579 (2001).
49. Curb JD, Abbott RD, Rodriguez BL et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 207, 2016-2020 (2003). The first and one of the few papers on CRP in a minority population (Asian-Americans). Demonstrates roughly equivalent risk of high CRP for stroke as for Caucasians.
50. Cao, JJ, Thach C, Manolio TA et al. C-reactive protein, carotid intimal-media thickness and incidence of ischemic stroke in the elderly: The Cardiovascular Health Study. Circulation 108, 166-170 (2003). One of the few papers on CRP and stroke in the elderly.
51. Curb JD, Abbott RD, MacLean CJ et al. Age-related changes in stroke risk in men with hypertension and normal blood pressure. Stroke 27, 819-824 (1996). Excellent paper on the controversial topic of blood pressure and stroke risk in the elderly.
52. Cesari M, Penninx BWJH, Newman AB et al. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition Study). Am. J. Cardiol. 92, 522-528 (2003).
53. van Exel E, Gussekloo J, de Craen AJM et al. Inflammation and stroke. The Leiden 85-Plus Study. Stroke 33, 1135-1138 (2002).
54. Koenig W. C-reactive protein and cardiovascular risk: has the time come for screening the general population? Clin. Chem. 47, 9-10 (2001).
55. Morrow DA, Ridker PM. High sensitivity C-reactive protein (hs-CRP): a novel risk marker in cardiovascular disease. Prev. Cardiol. 1, 13-16 (1999).
56. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103, 1813-1818 (2001).
57. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107, 363-369 (2003).
58. Ridker PM. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 108, E81-E85 (2003). Concise and readable summary of the case for CRP screening in CVD.
59. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin. Chem. 47, 28-30 (2001).
60. Gabay C, Kushner I. Acute-phase proteins and other systematic responses to inflammation. N. Engl. J. Med. 340, 448-454 (1999).
61. Du Clos TW. Function of C-reactive protein. Ann. Med. 32, 274-278 (2000).
62. Sakkinen P, Abbott RD, Curb JD et al. C-reactive protein and myocardial infarction. J. Clin. Epidemiol. 55, 445-451 (2002). The first and one of the few papers on CRP and myocardial infarction (MI) in a minority population (Asian-Americans). Demonstrates roughly equivalent risk of high CRP for MI compared with Caucasians.
63. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, 973-979 (1997). Classic early paper on CRP and CVD. Also shows CRP is lower in regular users of aspirin.
64. Ridker PM, Cushman M, Stampfer MJ et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97, 425-428 (1998).
65. Kuller LH, Tracy RP, Shaten J et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J. Epidemiol. 144, 537-547 (1996).
66. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843 (2000). High impact paper showing that CRP was more predictive than cholesterol screening for CVD in women.
67. Tracy RP, Lemaitre RN, Psaty BM et al. Relationship of C-reactive protein to the risk of cardiovascular disease in the elderly. Arterioscler. Thromb. Vasc. Biol. 17, 1121-1127 (1997). One of the few studies of CRP and CVD in the elderly.
68. Cesari M, Penninx BW, Newman AB et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108, 2317-2322 (2003). One of the few studies of CRP and CVD in the elderly. Suggests that interleukin-6 may be a better marker than CRP for stroke risk in the elderly.
69. Blake GJ, Ridker PM. Novel clinical nmrkers of vascular wall inflammation. Circ. Res. 89, 763-771 (2001).
70. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a) and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285, 2481-2485 (2001). Excellent comparison of the relative predictive abilities of different novel risk factors for atherosclerosis suggesting that CRP is more predictive than other novel risk factors and a better screening tool.
71. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97, 2007-2011 (1998).
72. Di Napoli M, Papa E Clinical use of C-reactive protein for prognostic stratification in ischemic stroke: has the time come for including it in the patient risk profile? Stroke 34, 375 (2003).
73. Tchernof A, Noran A, Sites CK et al. Weight loss reduced C-reactive protein levels in obese postmenopausal women. Circulation 105, 564-569 (2002).
74. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499-511 (2003). Comprehensive evidence-based summary statement and guidelines for health professionals regarding CRP testing.
75. Ridker PM, Buring JE, Shih J et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98, 731-733 (1998).
76. Ridker PM. Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. Eur. Heart J. 22, 2135-2137 (2001).
77. Ridker PM, Rifai N, Pfeffer M et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100, 230-235 (1999). Good paper showing statins can be effective in lowering CRP and thus may play a role in reducing inflammation.
78. Chew D, Bhatt DL, Robbins MA et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am. J. Cardiol. 88, 672-674 (2001).
79. Lincoff AM, Kereiakes DJ, Mascelli MA et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 104, 163-167 (2001).
80. Haffner SM, Greenberg AS, Weston WM et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation 106, 679-684 (2002). Interesting paper showing that the glitazones may also play a role in reducing inflammation and that CRP may be linked to glycemic control.
81. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145-153 (2000).
82. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin. Chem. 45, 2136-2141 (1999).
83. Roberts WL, Sedrick R, Moulton L et al. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin. Chem. 46 461-468 (2000).
84. Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347, 1557-1565 (2002). Good paper making the case that CRP may be more predictive than cholesterol for CVD.
85. Albert MA, Danielson E, Rifai N et al. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation CRP Evaluation (PRINCE). JAMA 286, 64-70 (2001).
86. Plenge JK, Hernandez TL, Weil KM et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106, 1447-1452 (2002).
87. Jenkins DJ, Kendall CW, Marchie A et al. Effects of a dietary portfolio of cholesterol-lowering foods vs. lovastatin on serum lipids and C-reactive protein. JAMA 290, 502-510 (2003). Excellent paper showing the powerful effects of specific dietary compounds in lowering lipids and CRP equivalent in efficacy to first generation statins.
88. Tomaszewski M, Charchar FJ, Przybycin M et al. Strikingly low circulating CRP concentrations in ultramarathon runners independent of markers of adiposity: how low can you go? Arterioscler. Thromb. Vasc. Biol. 23, 1640-1644 (2003). Provocative paper showing that exercise may lower CRP levels independent of body fat loss.
89. Alberts MJ. Stroke genetics update. Stroke 34, 342-344 (2003). Good current and concise review of this topic.
90. Tournier-Lasserve E. New players in the genetics of stroke. N. Engl. J. Med. 347, 1711-1712 (2002).
91. Brull DJ, Serrano N, Zito F et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 11, 2063-2069 (2003). Important new information on how subtle variations in human genes might affect CVD risk through variation in CRP levels.
92. Toyoda K, Chu Y, Heistad DD. Gene therapy for cerebral vascular disease: update 2003. Br. J. Pharmacol. 139, 1-9 (2003).